Tilmanocept
- Generic Name
- Tilmanocept
- Brand Names
- Lymphoseek
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1185986-76-8
- Unique Ingredient Identifier
- MDU8BQ474H
- Background
Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)).
- Associated Conditions
- Breast Cancer, Melanoma, Oral Cancer
- Associated Therapies
- -
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Navidea Biopharmaceuticals
- Target Recruit Count
- 134
- Registration Number
- NCT04947137
- Locations
- 🇺🇸
Innovation Medical Research Center, Palmetto Bay, Florida, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸Sun Research Institute, San Antonio, Texas, United States
Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Navidea Biopharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT04078191
- Locations
- 🇬🇧
Royal Free Hospital, London, England, United Kingdom
🇬🇧Barts Hospital, London, England, United Kingdom
🇺🇸Attune Health, Beverly Hills, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath